Enable Biosciences Selected for NIH Commercial Accelerator Program

October 9, 2018

Enable Biosciences has been selected from over 300 NIH Phase 2 grant awardees to participate in the 2018 - 2019 National Institutes of Health Commercial Accelerator Program (CAP). Per the NIH: “The CAP is well-regarded for its combination of deep domain expertise and access to industry connections which have resulted in measurable gains and accomplishments by participating companies.” The NIH further describes: “The program enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.”

“We are thrilled that the NIH has selected us out of a very competitive field for this critical commercial accelerator program award,” stated Enable’s CEO David Seftel, M.D. “We plan to use the exceptional resources of the program to do a deep dive into the best execution strategy to help bring our early diagnosis system for Type 1 diabetes to customers as soon as possible”

“Type I diabetes is an challenging disease to detect early on. Our ultra-sensitive and highly specific assay technology is designed to directly address this deficit”, explained Enable’s Chief Scientific Officer, Peter Robinson, PhD.

The 2018-2019 CAP also facilitates meetings with the FDA to assist in approval and review. “Our goal is to make our Type 1 diabetes  detection technology available across a range of form factors and platforms to serve the needs of both researchers and clinicians” stated Jason Tsai, PhD, Enable Biosciences’ Chief Technical Officer. He continued: “This way we can help our fellow scientists develop potential interventions that can interrupt this disease at the earliest possible stage, producing a positive impact on the lives of millions of children and young adults, who are most often afflicted with this disease.”

About Enable BiosciencesEnable Biosciences is a San Francisco-based diagnostics company commercializing licensed technology from UC Berkeley and Stanford University. Enable develops ultrasensitive and multiplex immunoassays to help diagnose diseases at their earliest and most effectively treatable stages. For more about Enable, visit www.enablebiosciences.com. For press inquiries, email press@enablebiosciences.com or call Peter Robinson, PhD (415-967-1460).